Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022.
Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
Protect your property and your loved ones with an all-in-one insurance solution!
WooClap is a tool that allows you to interactively engage your audience or learners during a present...
The first skincare brand dedicated to melanin-rich skin
Axiles Bionics, a spin-off of the VUB, is a leading research center in human robotics, striving to i...
Hytchers is a distribution solution that allows e-commerce parcels to be delivered by private indivi...
Originally producer of cold-pressed juice, the young startup Good Move had to reinvent itself in Mar...
Apaxen is a biotechnology company developing therapeutic anti-inflammatory drugs for the treatment o...
Bonjour Maurice is a Belgian design brand that offers reversible Montessori inspired clothing, helpi...
Noho’s mission is to contribute to the quality of life of people suffering from lymphedema.
Europea Residences selects the most sumptuous places around the world for you and your family. Disco...